Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
PharmaEssentia Corporation (6446.TW)
Taipei, TW
PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing therapies for human ailments, serving both the Taiwanese and international markets. Its product portfolio prominently features Ropeginterferon alfa-2b, indicated for the management of various hematological conditions including chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. Beyond this, the company's pipeline includes TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint antibodies, all under development for solid tumors. A specific combination, P1101 + anti PD-1, is being explored for hepatocellular carcinoma, while PEG-GCSF addresses neutropenia. Fundamentally, its comprehensive research and development initiatives span key therapeutic areas such as hematology, infectious diseases, and oncology. Established in 1990, PharmaEssentia Corporation maintains its headquarters in Taipei, Taiwan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +9.21% | +27.84% | +33.02% | +20.45% | +77.73% | +81.70% | +86.56% | +182.90% | +1,162.75% | +494.38% | +365.80% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 3 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+60.6% ★ Q1'26: +57.2% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+70.4% ★ Q1'26: +69.9% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+29.6% ★ Q1'26: +17.3% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+31.5% ★ Q1'26: +40.8% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+48.7% ★ Q1'26: +76.0% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+2.0% Q1'26: +0.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.16× ★ Q1'26: 0.10× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 3 Rev. Ana. 2 EPS Ana. |
Dec 2027 5 Rev. Ana. 4 EPS Ana. |
Dec 2028 1 Rev. Ana. 3 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
5.11B
est: 5.55B (-8.1%)
|
9.73B
est: 9.68B (+0.6%)
|
15.63B
est: 15.56B (+0.5%)
|
24.41B
23.10B – 25.50B
+56.9% YoY
|
37.99B
27.73B – 63.33B
+55.6% YoY
|
35.59B
35.59B – 35.59B
-6.3% YoY
|
| EBITDA |
-671.49M
est: -2.60B (+74.1%)
|
3.38B
est: -1.93B (+275.5%)
|
5.33B
est: -3.10B (+271.7%)
|
-4.87B
-5.08B – -4.60B
-56.9% YoY
|
-7.57B
-12.62B – -5.53B
-55.6% YoY
|
-7.10B
-7.10B – -7.10B
+6.3% YoY
|
| EBIT |
-940.24M
est: -2.78B (+66.2%)
|
3.02B
est: -2.31B (+230.8%)
|
4.93B
est: -3.71B (+232.9%)
|
-5.82B
-6.08B – -5.50B
-56.9% YoY
|
-9.05B
-15.09B – -6.61B
-55.6% YoY
|
-8.48B
-8.48B – -8.48B
+6.3% YoY
|
| Net Income |
-623.84M
est: -1.29B (+51.8%)
|
2.97B
est: 2.47B (+19.9%)
|
5.05B
est: 5.05B (+0.0%)
|
8.35B
7.92B – 8.79B
+65.6% YoY
|
13.95B
9.32B – 20.05B
+67.0% YoY
|
14.74B
11.18B – 22.87B
+5.7% YoY
|
| SGA |
4.18B
est: 7.46B (-43.9%)
|
4.23B
est: 10.26B (-58.7%)
|
5.29B
est: 16.50B (-68.0%)
|
25.89B
24.50B – 27.04B
+56.9% YoY
|
40.29B
29.41B – 67.17B
+55.6% YoY
|
37.75B
37.75B – 37.75B
-6.3% YoY
|
| EPS |
-1.74
est: -3.57 (+51.2%)
|
8.08
est: 6.69 (+20.8%)
|
13.64
est: 13.66 (-0.1%)
|
22.88
21.41 – 23.75
+67.5% YoY
|
40.42
25.20 – 54.21
+76.7% YoY
|
39.85
30.23 – 61.84
-1.4% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-13 | B | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-12 | B | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-11 | B | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-08 | B | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-07 | B | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-06 | B | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-05 | B | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-04 | B | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-04-30 | B | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-04-29 | B | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-04-28 | B | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-04-27 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-24 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-23 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-22 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-21 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-20 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-17 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-16 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-15 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ko-Chung Lin | Founder, Chief Executive Officer, Chief Strategy Officer & Director | 15M | male |
| Ching-Leou Teng | Chairman & Chief Pharmaceutical Officer | 14M | — |
| Chan-Kou Hwang | President, GM & Director | 13M | male |
| Albert Qin | Chief Medical Officer | 7M | — |
| Yen-Tung Luan | Chief Operating Officer of Taichung Plant | 6M | male |
| Lih-Ling Lin | Chief Scientific Officer | — | female |
| Narihisa Miyachi | Head of Japan Medical Affairs | — | — |
| Samuel Lin | Vice President and Head of Business Operations & Strategy | — | male |
| Snow Chang | Senior Director of Finance | — | female |
| Wu Kuo-Hsiung | Chief of Taichung Plant | — | — |
| Hsing-I Chen | General Counsel | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 6446.TW
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
